News

As the number of patients with multiple myeloma and lymphoma treated with CAR-T therapy increases, health systems are shifting post-infusion care from inpatient to outpatient settings. Research presented at the annual meeting of the American Society of Hematology shows the change slices costs by $19,180.

Tranexamic acid given during noncardiac surgery reduced blood transfusions by 2.4% without increasing blood clots, potentially saving millions of transfusion units annually nationwide.

A phase 3 trial showed that Jaypirca improved progression-free survival in newly diagnosed patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with standard chemotherapy/rituximab regimen.

Dermatologists explore chronic itch advancements, revealing new treatments and insights into its complex biology, lifestyle impacts and future care strategies.

Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of awareness around the therapy are barriers to care, according to George Eastwood, Executive Director of the Emily Whitehead Foundation.

In this interview, George Eastwood, Executive Director of the Emily Whitehead Foundation and CAR T Vision steering committee member discusses barriers and strategies for expanding access to CAR T-cell therapy.

Early results from the LINKER-MM4 trial show high response rates for linvoseltamab, offering new hope for newly diagnosed patients.

Early results from the LINKER-MM4 trial reveal promising response rates for linvoseltamab in newly diagnosed multiple myeloma patients, with manageable side effects.

Jaypirca demonstrated non-inferior response rates compared with Imbruvica in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, with fewer cardiovascular events and dose reductions.

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with standard chemotherapy in patients with acute myeloid leukemia who are fit for transplant.

The chief medical officer of Genetix Biotherapeutics, formerly known as Bluebird bio, discusses timelines and operational challenges of the gene therapies Zynteglo for beta thalassemia and Lyfgenia for sickle cell disease.

About one-third of families with a child undergoing treatment for acute lymphoblastic leukemia experienced catastrophic income loss during therapy, with many developing new material hardships over the two-year course, underscoring the need for ongoing financial screening and support.

IV iron infusions were found to be safe for anemic patients hospitalized with acute bacterial infections and were associated with improved survival and higher hemoglobin levels, challenging long-held concerns that iron worsens infections.

The patient died from vent-occlusive liver disease, a well-characterized side effect of the busulfan, the myeloablative chemotherapy used to prepare the bone marrow for engraftment with the Casgevy-modified blood stem cells.

Adults with sickle cell disease face longer emergency department wait times for pain treatment than children, with women experiencing more delays than men.

The AI-powered imaging technology quantifies the extent of fibrosis on CT scans and also measures other features, such as ground-glass opacification.

Multiple sclerosis patients who completed hydrotherapy courses had better symptom outcomes than patients who participated in physical therapy sessions on land.

Early-stage research suggests a strategy for suppressing bladder cancer growth at the RNA level.

ACIP votes to change hepatitis B vaccine guidelines, delaying newborn doses for HepB-negative mothers, sparking debate among medical professionals.

In this episode of his “Conversations With Perry and Friends” podcast, Perry Cohen, Pharm.D., a member of the Managed Healthcare Executive editorial advisory board, spoke with Rita Shane, vice president and chief pharmacy officer at Cedars-Sinai Medical Center in Los Angeles.

Self-administered clinical hypnosis cut hot flash frequency and severity by more than 50% in postmenopausal women, showing effectiveness comparable to therapist-led treatment in a recent randomized trial.

By identifying the isoforms of the prostate-specific antigen (PSA), the new test may distinguish between prostate cancer and other causes of elevated PSA levels.

ACIP reviews hepatitis B vaccine guidelines, focusing on infant immunization schedules and new recommendations during its December 2025 meeting.

The new approach prevented diabetes onset in a mouse model and also reversed longstanding diabetes.

The Melanoma Research Alliance launched a national biorepository at the University of Colorado to collect melanoma samples, focusing on rare subtypes for diagnostic and treatment research.

New technology generates “nanotube highways” between cancer cells, enabling better drug penetration and tumor-killing effectiveness while minimizing harm to surrounding healthy tissue in animal studies of bladder cancer.